NCT02856815View on ClinicalTrials.gov

"Safety and Efficacy of Immuncell-LC in TACE Therapy"

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

May 28, 2018

Primary Completion Date

August 11, 2020

Study Completion Date

September 22, 2022

Conditions
Carcinoma, Hepatocellular
Interventions
BIOLOGICAL

Immuncell-LC

Activated T lymphocyte : intravenous dripping of 200ml (1 x 10\^9 \~ 2 x 10\^10 lymphocytes / 60kg adult) for 1 hour

Trial Locations (3)

06591

Seoul St.Mary's Hospital, Seoul

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

GC Cell Corporation

INDUSTRY